Study Summary
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Want to learn more about this trial?
Request More InfoInterventions
Allogeneic anti-CD7 CAR-T cells (BEAM-201)BIOLOGICAL
The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States |